New designer benzodiazepines use in Barcelona
New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet. To describe the p...
Saved in:
Published in | European psychiatry Vol. 41; no. S1; p. S874 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Masson SAS
01.04.2017
|
Online Access | Get full text |
Cover
Loading…
Abstract | New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet.
To describe the presence of new designer benzodiazepines in samples delivered to energy control since 2010 to 2016 in Barcelona.
From 2010 to 2016, 24,551 samples were delivered to energy control. Among this samples 43 (0.175%) were analysed as benzodiazepines. They were analyzed by energy control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by gas chromatography-mass spectrometry.
From the 43 samples analyzed as benzodiazepines, 1 (2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012, 2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21 (48.83%) in 2016.
The data shows that new designer benzodiazepines use is increasing in Barcelona, especially in the last two years. Abuse an addiction to these drugs may be a new public health problem in Barcelona. Unknown side effects may appear due to lack of information about pharmacokinetic profile of these drugs. |
---|---|
AbstractList | Introduction
New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet.
Objective
To describe the presence of new designer benzodiazepines in samples delivered to energy control since 2010 to 2016 in Barcelona.
Methods
From 2010 to 2016, 24,551 samples were delivered to energy control. Among this samples 43 (0.175%) were analysed as benzodiazepines. They were analyzed by energy control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by gas chromatography-mass spectrometry.
Results
From the 43 samples analyzed as benzodiazepines, 1 (2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012, 2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21 (48.83%) in 2016.
Discussion
The data shows that new designer benzodiazepines use is increasing in Barcelona, especially in the last two years. Abuse an addiction to these drugs may be a new public health problem in Barcelona. Unknown side effects may appear due to lack of information about pharmacokinetic profile of these drugs.
Disclosure of interest
The authors have not supplied their declaration of competing interest. New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet. To describe the presence of new designer benzodiazepines in samples delivered to energy control since 2010 to 2016 in Barcelona. From 2010 to 2016, 24,551 samples were delivered to energy control. Among this samples 43 (0.175%) were analysed as benzodiazepines. They were analyzed by energy control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by gas chromatography-mass spectrometry. From the 43 samples analyzed as benzodiazepines, 1 (2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012, 2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21 (48.83%) in 2016. The data shows that new designer benzodiazepines use is increasing in Barcelona, especially in the last two years. Abuse an addiction to these drugs may be a new public health problem in Barcelona. Unknown side effects may appear due to lack of information about pharmacokinetic profile of these drugs. |
Author | De Dios Felis, M. Grifell Guàrdia, M. Torrens Melich, M. Quintana Mathe, P. Pérez González, S. Sanagustín Bosqued, D. Monteagudo Gimeno, E. Galindo Guarín, L. Trabsa Biskri, A. |
Author_xml | – sequence: 1 givenname: S. surname: Pérez González fullname: Pérez González, S. – sequence: 2 givenname: M. surname: De Dios Felis fullname: De Dios Felis, M. – sequence: 3 givenname: E. surname: Monteagudo Gimeno fullname: Monteagudo Gimeno, E. – sequence: 4 givenname: D. surname: Sanagustín Bosqued fullname: Sanagustín Bosqued, D. – sequence: 5 givenname: A. surname: Trabsa Biskri fullname: Trabsa Biskri, A. – sequence: 6 givenname: M. surname: Grifell Guàrdia fullname: Grifell Guàrdia, M. – sequence: 7 givenname: L. surname: Galindo Guarín fullname: Galindo Guarín, L. – sequence: 8 givenname: P. surname: Quintana Mathe fullname: Quintana Mathe, P. – sequence: 9 givenname: M. surname: Torrens Melich fullname: Torrens Melich, M. |
BookMark | eNqFj9FKwzAYhYNMsJs-gtAXaM3fNE1yJTp0CkNv9DqkyV9JmWlJnLI9vR313qtzc87H-ZZkEYaAhFwDLYFCc9OXuI9jOpQVBVFSKEFweUYyEEIWjEu-IBlVVV0oxuQFWabU06lJaZOR4gV_cofJfwSMeYvhODhvjjj6gCnfJ8x9yO9NtLgbgrkk553ZJbz6yxV5f3x4Wz8V29fN8_puW1jgtSw6q9Agc6rtECQ3nDNoRG0AG6W4kEZ0FXABFiRrHKtYqyrXMAUdb52UnK0In7k2DilF7PQY_aeJBw1Un5x1r2dnfXLWFPTJedrdzjuczn17jDpZj8Gi8xHtl3aD_4fwC-1fYzU |
CitedBy_id | crossref_primary_10_1111_add_15734 |
ContentType | Journal Article |
Copyright | 2017 |
Copyright_xml | – notice: 2017 |
DBID | AAYXX CITATION |
DOI | 10.1016/j.eurpsy.2017.01.1758 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1778-3585 |
EndPage | S874 |
ExternalDocumentID | 10_1016_j_eurpsy_2017_01_1758 S092493381731773X |
GroupedDBID | --- --K --M .1- .FO .~1 09C 09E 0R~ 0SF 1B1 1P~ 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8FI 8FJ 8P~ AABNK AACTN AAEDT AAEDW AAEED AAFWJ AAIKJ AAKOC AALRI AANRG AAOAW AAQFI AAQXK AASVR AAXUO ABBQC ABBZL ABFNM ABIVO ABJNI ABMZM ABUWG ABXDB ABYKQ ACDAQ ACGFS ACHQT ACIUM ACQPF ACZWT ADAZD ADBBV ADDNB ADEZE ADKIL ADMUD ADOVH ADVJH AEBAK AEBPU AEKER AENCP AENEX AEVXI AEYHU AFCTW AFKRA AFPKN AFRHN AFTJW AGABE AGHFR AGJUD AGUBO AGYEJ AHIPN AHRGI AITUG AJBFU AJOXV AJPFC AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQJOH ASPBG AVWKF AZFZN AZQEC BENPR BLXMC BLZWO CCPQU CCUQV CFBFF CGQII CJCSC CS3 DOHLZ DU5 DWQXO EBS EFLBG EGQIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYUFA G-Q GBLVA GNUQQ GROUPED_DOAJ HVGLF HZ~ IHE IKXGN IOO IPYYG J1W LCYCR LN9 LW7 M2M M41 MO0 N9A NCXOZ NZEOI O-L O9- OAUVE OH0 OK1 OU- OZT P-8 P-9 P2P PC. PIMPY PSYQQ Q38 R2- RCA RIG ROL RPM RPZ SCC SDF SDG SDP SES SEW SSZ T5K UHS UKHRP UV1 WFFJZ Z5R ~G- AAYXX ABVZP ABXAU ADVLN AKRWK ALIPV CCQAD CITATION CTKSN |
ID | FETCH-LOGICAL-c1548-fc9eae3d9bfe185a5531674a1e699578a7f21571c1836d323b92d6391f5bd8853 |
IEDL.DBID | .~1 |
ISSN | 0924-9338 |
IngestDate | Thu Sep 26 16:14:43 EDT 2024 Fri Feb 23 02:24:07 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | S1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1548-fc9eae3d9bfe185a5531674a1e699578a7f21571c1836d323b92d6391f5bd8853 |
ParticipantIDs | crossref_primary_10_1016_j_eurpsy_2017_01_1758 elsevier_sciencedirect_doi_10_1016_j_eurpsy_2017_01_1758 |
PublicationCentury | 2000 |
PublicationDate | April 2017 2017-04-00 |
PublicationDateYYYYMMDD | 2017-04-01 |
PublicationDate_xml | – month: 04 year: 2017 text: April 2017 |
PublicationDecade | 2010 |
PublicationTitle | European psychiatry |
PublicationYear | 2017 |
Publisher | Elsevier Masson SAS |
Publisher_xml | – name: Elsevier Masson SAS |
SSID | ssj0017006 |
Score | 2.1982977 |
Snippet | New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that... Introduction New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | S874 |
Title | New designer benzodiazepines use in Barcelona |
URI | https://dx.doi.org/10.1016/j.eurpsy.2017.01.1758 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07a8MwEBYhQ-lS-qTpI2joqjh-yJbGNjSUQrq0gWxCL0NCcUweQzP0t_fOjz6gdOhocwL5TrrvzvruRMiNkxmArtBMcGNYEoaSySjlTDtIgYaJttLiD_3JU_owTR5nfNYho7YWBmmVje-vfXrlrZs3QaPNoJzPg-chpg4xdpgDDMziGVawA_zBmh68f9I8sP1cdV4Jwgylv6p4ggX2VizXb0jwyrB5J0Cp-B2fvmHO-JAcNMEiva3nc0Q6vjgme5PmOPyEMHBR1FUcDL-ixhe7JZh750vkstPt2tN5Qe-wmvEVAu5TMh3fv4weWHP_AbOYSLDcSq997KTJPcCq5hzL1hMd-lRK2Gk6ywGws9DCtkxdHMVGRg4ijjDnxgnA4TPSLZaFPyc0AxlrjTEpt4mw2hjBpRF5pG3s08z0yKD9alXWbS5Uy_9aqFpNCtWkhqFCNfWIaHWjfthLgSv-e-jF_4dekn18rJkzV6S7WW39NQQFG9OvrN6vUuoPUVm1Ew |
link.rule.ids | 315,783,787,867,4509,27936,27937,45597 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZKkYAF8RTlmYHVTdPEiT1CRVWg7UIrdbNsx5FaoTTqY6ADv527PHhIiIE1OUvJ2b7vLv7uCyG3sYgAdLminGlNA88TVLRDRlUMJVArUEYY_KA_GIa9cfA0YZMa6VS9MEirLGN_EdPzaF1ecUtvutl06r60sHTwUWEOMDDyJ1tkO8D8GBZ18_2T54H6c_mBJVhTNP9q43FnKK6YLd-Q4RWheidgKf8doL6BTveA7JfZonNXPNAhqdn0iOwMyvPwY0IhRjlxTsKwC0fbdDOH-d7YDMnsznppnWnq3GM74ytk3Cdk3H0YdXq0_AECNVhJ0MQIq6wfC51YwFXFGPatB8qzoRCw1VSUAGJHnoF9GcZ-29eiHUPK4SVMxxyA-JTU03lqz4gTgY0xWuuQmYAbpTVnQvOkrYxvw0g3SLN6a5kVOheyIoDNZOEmiW6SLU-imxqEV76RPyZMQiz-e-j5_4fekN3eaNCX_cfh8wXZw1sFjeaS1FeLtb2CDGGlr_MV8AFIn7dF |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+designer+benzodiazepines+use+in+Barcelona&rft.jtitle=European+psychiatry&rft.au=P%C3%A9rez+Gonz%C3%A1lez%2C+S.&rft.au=De+Dios+Felis%2C+M.&rft.au=Monteagudo+Gimeno%2C+E.&rft.au=Sanagust%C3%ADn+Bosqued%2C+D.&rft.date=2017-04-01&rft.issn=0924-9338&rft.eissn=1778-3585&rft.volume=41&rft.issue=S1&rft.spage=S874&rft.epage=S874&rft_id=info:doi/10.1016%2Fj.eurpsy.2017.01.1758&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_eurpsy_2017_01_1758 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0924-9338&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0924-9338&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0924-9338&client=summon |